Jeffrey V. Lazarus (born 1969) is a professor of global health at the CUNY Graduate School of Public Health and Health Policy and head of the Public Health Liver Group at the Barcelona Institute for Global Health in Barcelona.[1]
His work focuses on global health policy, viral hepatitis, and steatotic liver disease, and he has been interviewed in international media on public health issues.[2][3][4]
Early life and education
editLazarus earned a Bachelor of Arts in Latin American Studies and Romance Languages from New York University, a Master of Arts in Latin American Studies from Georgetown University, and a Master of International Health from the University of Copenhagen.[1] He received a PhD in public health from Lund University.[1]
Career
editLazarus has held positions in international health organizations, including the World Health Organization Regional Office for Europe and the Global Fund to Fight AIDS, Tuberculosis and Malaria.[1]
He contributed to the establishment of a WHO Collaborating Centre on HIV and Viral Hepatitis at the University of Copenhagen and co-founded Health Systems Global.[1]
He chaired the Healthy Livers, Healthy Lives initiative and serves as director of the Global Think-Tank on Steatotic Liver Disease.[5]
The Global Think-Tank on Steatotic Liver Disease has convened international experts and produced policy recommendations published in The Lancet Regional Health – Europe.[6]
He has also collaborated with clinical and research institutions and participated in public health initiatives on steatotic liver disease, including the MASH Cities initiative with the Mount Sinai Health System and expert debates organized by the Fundación ”la Caixa”.[7][8]
Research and impact
editLazarus's research focuses on global health policy, viral hepatitis, and liver disease prevention, with an emphasis on public health approaches to diagnosis, treatment, and care.[1]
He was a co-author of a consensus statement on non-alcoholic fatty liver disease (NAFLD) published in Nature Reviews Gastroenterology & Hepatology.[9]
He was also a co-author of a Commission on viral hepatitis elimination published in The Lancet Gastroenterology & Hepatology.[10]
His work has also contributed to international efforts on viral hepatitis elimination, including policy discussions associated with the World Health Organization.[11]
Research on fatty liver disease and metabolic dysfunction–associated steatotic liver disease (MASLD) has been widely covered in international media.[3][12]
He has authored or co-authored hundreds of peer-reviewed publications.[1]
Awards and honors
editReferences
edit- 1 2 3 4 5 6 7 "Jeffrey Lazarus". Barcelona Institute for Global Health. Retrieved 8 April 2026.
- ↑ "Jeffrey V. Lazarus: "Mientras exista una variante en circulación como ómicron hay que prepararse"". Heraldo de Aragón. 12 December 2022. Retrieved 8 April 2026.
- 1 2 "Millions in west do not know they have aggressive fatty liver disease, study says". The Guardian. 5 June 2025. Retrieved 8 April 2026.
- ↑ "Chronic diseases are squeezing economies. Leaders don't have much of a plan". Politico Europe. 25 September 2025. Retrieved 8 April 2026.
- ↑ "Jeffrey V. Lazarus, PhD". American Association for the Study of Liver Diseases. Retrieved 8 April 2026.
- ↑ "Global Think-tank on Steatotic Liver Disease 2025 meeting". The Lancet Regional Health – Europe. 2025. Retrieved 8 April 2026.
- ↑ "Mount Sinai's MASLD/MASH Center of Excellence Focuses on Liver Disease Science and Treatment". Mount Sinai Health System. Retrieved 8 April 2026.
- ↑ "Nuevo Debate CaixaResearch dedicado al hígado graso, una enfermedad silenciosa que afecta a más de un tercio de la población". Fundación ”la Caixa”. 8 February 2024. Retrieved 8 April 2026.
- ↑ Lazarus, Jeffrey V. (2022). "Advancing the global public health agenda for NAFLD: a consensus statement". Nature Reviews Gastroenterology & Hepatology. 19 (1): 60–78. doi:10.1038/s41575-021-00523-4. Retrieved 8 April 2026.
- ↑ Cooke, Graham S. (2019). "Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission". The Lancet Gastroenterology & Hepatology. 4 (2): 135–184. doi:10.1016/S2468-1253(18)30270-X. Retrieved 8 April 2026.
- ↑ "Global health sector strategy on viral hepatitis 2016–2021". World Health Organization. Retrieved 8 April 2026.
- ↑ "La epidemia del hígado graso: el órgano en el que se ensaña el mal estilo de vida". El País. 24 June 2023. Retrieved 8 April 2026.
- ↑ "American Liver Foundation honors Professor Jeffrey V. Lazarus". American Liver Foundation. Retrieved 8 April 2026.
- ↑ "2025 AACE Award Recipients". American Association of Clinical Endocrinology. Retrieved 8 April 2026.